Free Trial
NASDAQ:BMRN

BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis

$84.43
-0.88 (-1.03%)
(As of 07/23/2024 ET)
Today's Range
$84.37
$85.85
50-Day Range
$74.43
$85.89
52-Week Range
$73.68
$99.56
Volume
1.51 million shs
Average Volume
1.91 million shs
Market Capitalization
$16.03 billion
P/E Ratio
78.91
Dividend Yield
N/A
Price Target
$102.00

BioMarin Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.55 Rating Score
Upside/​Downside
20.8% Upside
$102.00 Price Target
Short Interest
Healthy
4.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
0.54mentions of BioMarin Pharmaceutical in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$5.21 M Sold Last Quarter
Proj. Earnings Growth
43.22%
From $1.99 to $2.85 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.73 out of 5 stars

Medical Sector

53rd out of 897 stocks

Pharmaceutical Preparations Industry

14th out of 426 stocks

BMRN stock logo

About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN Stock Price History

BMRN Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
BioMarin Pharmaceutical Inc.
See More Headlines
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/24/2024
Today
7/23/2024
Next Earnings (Estimated)
7/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BMRN
CUSIP
09061G10
Employees
3,401
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$102.00
High Stock Price Target
$140.00
Low Stock Price Target
$72.00
Potential Upside/Downside
+19.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55
Research Coverage
20 Analysts

Profitability

Net Income
$167.65 million
Pretax Margin
9.60%

Debt

Sales & Book Value

Annual Sales
$2.42 billion
Cash Flow
$1.82 per share
Book Value
$26.29 per share

Miscellaneous

Free Float
186,367,000
Market Cap
$16.25 billion
Optionable
Optionable
Beta
0.32

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

Key Executives


BMRN Stock Analysis - Frequently Asked Questions

How have BMRN shares performed this year?

BioMarin Pharmaceutical's stock was trading at $96.42 at the beginning of 2024. Since then, BMRN shares have decreased by 12.4% and is now trading at $84.43.
View the best growth stocks for 2024 here
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its earnings results on Wednesday, April, 24th. The biotechnology company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.37 by $0.12. The biotechnology company had revenue of $648.83 million for the quarter, compared to the consensus estimate of $649.75 million. BioMarin Pharmaceutical had a net margin of 8.31% and a trailing twelve-month return on equity of 5.34%.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

Who are BioMarin Pharmaceutical's major shareholders?

Top institutional shareholders of BioMarin Pharmaceutical include DNB Asset Management AS (0.54%), Sumitomo Mitsui Trust Holdings Inc. (0.23%), Assenagon Asset Management S.A. (0.19%) and Swedbank AB (0.15%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Richard A Meier, Jeffrey Robert Ajer, Brian Mueller, George Eric Davis, Charles Greg Guyer, V Bryan Lawlis, Erin Burkhart, Mark J Alles and Dennis Slamon.
View institutional ownership trends
.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX) and Micron Technology (MU).

This page (NASDAQ:BMRN) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners